{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":37,"description":"All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.\n\n1540 nanometer Erbium glass laser: Subjects will receive laser treatment by dermatologist at week 0 and week 4.","id":"EG000","otherNumAffected":37,"otherNumAtRisk":37,"seriousNumAffected":0,"seriousNumAtRisk":37,"title":"All Subjects"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Transient expected redness at the site of laser applicaiton, resolving within 3 days of treatment without sequela.\n\n.","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":37,"numEvents":87}],"term":"Transient Erythema"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Transient expected swelling at site of laser application, resolving within 3 days of treatment without sequela.","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":37,"numEvents":87}],"term":"Transient Edema"}],"timeFrame":"Adverse events were collected from baseline to week 12."}